124 related articles for article (PubMed ID: 22360644)
1. Increase in circulating endothelial progenitor cells predicts response in patients with advanced non-small-cell lung cancer.
Sakamori Y; Masago K; Ohmori K; Togashi Y; Nagai H; Okuda C; Kim YH; Ichiyama S; Mishima M
Cancer Sci; 2012 Jun; 103(6):1065-70. PubMed ID: 22360644
[TBL] [Abstract][Full Text] [Related]
2. Late release of circulating endothelial cells and endothelial progenitor cells after chemotherapy predicts response and survival in cancer patients.
Roodhart JM; Langenberg MH; Vermaat JS; Lolkema MP; Baars A; Giles RH; Witteveen EO; Voest EE
Neoplasia; 2010 Jan; 12(1):87-94. PubMed ID: 20072657
[TBL] [Abstract][Full Text] [Related]
3. Dynamics of circulating endothelial cells and endothelial progenitor cells in breast cancer patients receiving cytotoxic chemotherapy.
Kuo YH; Lin CH; Shau WY; Chen TJ; Yang SH; Huang SM; Hsu C; Lu YS; Cheng AL
BMC Cancer; 2012 Dec; 12():620. PubMed ID: 23268621
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016.
Ikeda S; Kato T; Ogura T; Sekine A; Oda T; Masuda N; Igawa S; Katono K; Otani S; Yamada K; Saito H; Kondo T; Hosomi Y; Nakahara Y; Nishikawa M; Utumi K; Misumi Y; Yamanaka T; Sakamaki K; Okamoto H
BMC Cancer; 2018 Mar; 18(1):241. PubMed ID: 29499653
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy and prognostic factors of 178 advanced non-small lung cancer patients undergoing different second-line chemotherapeutic regimens].
Kong Q; Wang XY; Jiang RC; Ba Y; Li K
Zhonghua Zhong Liu Za Zhi; 2016 Apr; 38(4):294-9. PubMed ID: 27087377
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of plasma vascular endothelial growth factor in monitoring first-line chemotherapy in patients with advanced non-small cell lung cancer.
Kumar S; Guleria R; Singh V; Bharti AC; Mohan A; Das BC
BMC Cancer; 2009 Dec; 9():421. PubMed ID: 19958548
[TBL] [Abstract][Full Text] [Related]
7. Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy.
Xu C; Hao K; Hu H; Sheng Z; Yan J; Wang Q; Yu L
Lung Cancer; 2014 Nov; 86(2):268-73. PubMed ID: 25262426
[TBL] [Abstract][Full Text] [Related]
8. Peripheral blood progenitor cell cycle kinetics following priming with pIXY321 in patients treated with the "ICE" regimen.
Murren JR; Gollerkeri A; Anderson S; Lutzker S; Del Prete S; Zelterman D; Garrison L; Smith B
Yale J Biol Med; 1998; 71(5):355-65. PubMed ID: 10527363
[TBL] [Abstract][Full Text] [Related]
9. A prognostic model for platinum-doublet as second-line chemotherapy in advanced non-small-cell lung cancer patients.
Mo H; Hao X; Liu Y; Wang L; Hu X; Xu J; Yang S; Xing P; Shi Y; Jia B; Wang Y; Li J; Wang H; Wang Z; Sun Y; Shi Y
Cancer Med; 2016 Jun; 5(6):1116-24. PubMed ID: 26993156
[TBL] [Abstract][Full Text] [Related]
10. Circulating endothelial cells in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
Kawaishi M; Fujiwara Y; Fukui T; Kato T; Yamada K; Ohe Y; Kunitoh H; Sekine I; Yamamoto N; Nokihara H; Watabe T; Shimoda Y; Arao T; Nishio K; Tamura T; Koizumi F
J Thorac Oncol; 2009 Feb; 4(2):208-13. PubMed ID: 19179898
[TBL] [Abstract][Full Text] [Related]
11. Circulating endothelial and endothelial progenitor cells in non-small-cell lung cancer.
Fleitas T; Martínez-Sales V; Gómez-Codina J; Martín M; Reynés G
Clin Transl Oncol; 2010 Aug; 12(8):521-5. PubMed ID: 20709649
[TBL] [Abstract][Full Text] [Related]
12. Circulating endothelial cells and microparticles for prediction of tumor progression and outcomes in advanced non-small cell lung cancer.
Najjar F; Alammar M; Al-Massarani G; Almalla N; Aljapawe A; Ikhtiar A
Cancer Biomark; 2017 Sep; 20(3):333-343. PubMed ID: 28800312
[TBL] [Abstract][Full Text] [Related]
13. Metronomic vinorelbine (oral) in combination with sorafenib in advanced non-small cell lung cancer.
Tan EH; Tan DS; Li WY; Haaland B; Ang MK; Chau NM; Toh CK; Tan IB; Koh TS; Thng CH; Chowbay B; Hui KM; Lim WT; Ng QS
Lung Cancer; 2015 Jun; 88(3):289-96. PubMed ID: 25896396
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer.
Yoh K; Ishii G; Yokose T; Minegishi Y; Tsuta K; Goto K; Nishiwaki Y; Kodama T; Suga M; Ochiai A
Clin Cancer Res; 2004 Mar; 10(5):1691-7. PubMed ID: 15014021
[TBL] [Abstract][Full Text] [Related]
15. Baseline levels and decrease in serum soluble intercellular adhesion molecule-1 during chemotherapy predict objective response and survival in patients who have advanced non-small-cell lung cancer.
Qian Q; Zhan P; Yu L; Shi Y; Cheng J; Wei S; Wang Q; Song Y
Clin Lung Cancer; 2011 Mar; 12(2):131-7. PubMed ID: 21550560
[TBL] [Abstract][Full Text] [Related]
16. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.
Thatcher N; Hirsch FR; Luft AV; Szczesna A; Ciuleanu TE; Dediu M; Ramlau R; Galiulin RK; Bálint B; Losonczy G; Kazarnowicz A; Park K; Schumann C; Reck M; Depenbrock H; Nanda S; Kruljac-Letunic A; Kurek R; Paz-Ares L; Socinski MA;
Lancet Oncol; 2015 Jul; 16(7):763-74. PubMed ID: 26045340
[TBL] [Abstract][Full Text] [Related]
17. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.
Pirker R; Pereira JR; Szczesna A; von Pawel J; Krzakowski M; Ramlau R; Vynnychenko I; Park K; Yu CT; Ganul V; Roh JK; Bajetta E; O'Byrne K; de Marinis F; Eberhardt W; Goddemeier T; Emig M; Gatzemeier U;
Lancet; 2009 May; 373(9674):1525-31. PubMed ID: 19410716
[TBL] [Abstract][Full Text] [Related]
18. The clinical significance of CXCL16 in the treatment of advanced non-small cell lung cancer.
Shibata Y; Kobayashi N; Sato T; Nakashima K; Kaneko T
Thorac Cancer; 2020 May; 11(5):1258-1264. PubMed ID: 32163231
[TBL] [Abstract][Full Text] [Related]
19. Neutrophil-to-lymphocyte ratio is superior to platelet-to-lymphocyte ratio as a prognostic predictor in advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy.
Guo D; Li M; Chen D; Jing W; Zhu H; Fu L; Kong L; Yue J; Yu J
Future Oncol; 2019 Feb; 15(6):625-635. PubMed ID: 30430864
[TBL] [Abstract][Full Text] [Related]
20. Serum vascular endothelial growth factor (VEGF) and bcl-2 levels in advanced stage non-small cell lung cancer.
Tas F; Duranyildiz D; Oguz H; Camlica H; Yasasever V; Topuz E
Cancer Invest; 2006 Oct; 24(6):576-80. PubMed ID: 16982461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]